Document is current
Any future updates will be listed below
-
Authors
Carreño, Mar https://orcid.org/0000-0001-9347-275X
Kim-Wisskirchen, In-Ha
Forcadell Ferré, Marta
Muñiz, Paula
Valiante, Cristian
-
Funding
Funding for this research was provided by:
Neuraxpharm (Funding of the writing of the manuscript)
- License Information
-
More Information
Article History
Received: 20 June 2025
Accepted: 29 September 2025
First Online: 28 October 2025
Declarations
:
: MC has received research grants from Eisai and Angelini Pharma; fees for speaking and advisory boards from Biocodex, Arvelle, Neuraxpharm, UCB, Eisai, Jazz Pharmaceuticals, and Livanova; and fees for teaching activities from Angelini Pharma and UCB Pharma. IKN and MFF are full-time employees of Neuraxpharm. PM and CV are full-time employees of CTI Laboratory Services.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MC: conceptualization, methodology, writing and original draft preparation, writing – review and editing. IKN and MFF: conceptualization, methodology, funding acquisition, writing – review & editing. PM and CV: methodology, writing – review & editing. All authors approved the final version for publication and agree to be accountable for the work presented.
